Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy and CNS effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). Discontinue Delafloxacin immediately at the first signs or symptoms of any serious adverse reactionFluoroquinolones have been associated with an increased risk of tendinitis and tendon rupture in all ages. Tendinitis or tendon rupture can occur, within hours or days of starting a fluoroquinolone, or even several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally. Discontinue Delafloxacin immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon.Fluoroquinolones have been associated with an increased risk of peripheral neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including Delafloxacin. Discontinue Delafloxacin immediately if the patient experiences symptoms of peripheral neuropathy.Fluoroquinolones, including Delafloxacin, have been associated with an increased risk of psychiatric adverse reactions. Toxic psychosis; hallucinations or paranoia; depression or suicidal thoughts or acts; delirium, disorientation, confusion or disturbances in attention; anxiety, agitation or nervousness; insomnia or nightmares; memory impairment may occur. Discontinue Delafloxacin immediately if the patient experiences symptoms.Fluoroquinolones have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (including pseudotumor cerebri), dizziness and tremors. Discontinue Delafloxacin immediately if the patient experiences symptoms.Fluoroquinolones have neuromuscular blocking activity and may cause muscle weakness in persons with myasthenia gravis. Avoid Delafloxacin in patients with known history of myasthenia gravis.Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, have been reported in patients receiving fluoroquinolone therapy. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticarial and itching. Discontinue Delafloxacin at the first appearance of a skin rash or any other sign of hypersensitivity.Clostridium difficile-associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including Delafloxacin, with severity ranging from mild diarrhea to fatal colitis.Increased risk of aortic aneurysm and dissection have been reported within two months following use of fluoroquinolones, particularly in elderly patients.Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent or with insulin. In these patients, careful monitoring of blood glucose is recommended. Severe cases of hypoglycemia resulting in coma or death have been reported with other fluoroquinolones. If a hypoglycemic reaction occurs, discontinue Delafloxacin immediately.Delafloxacin can make you feel dizzy and lightheaded. Do not drive, operate machinery or do other activities that require mental alertness or coordination until you know how Delafloxacin affects you.
